Century Therapeutics, Inc.
IPSC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001850119
In the last 90 days, Century Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 100 institutions reported holding it in 13F filings for Q2 2026, worth $387.0M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Century Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 64 | 64 | 0 |
| Shares | 20.0M | 19.3M | −710.0K (−3.5%) |
| Value | $69.5M | $61.0M | −$8.50M (−12.2%) |
New holders (4)
Institutions that held Century Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Bridgeway Capital Management, LLC | 165,000 | $521.4K | 0.01% |
| Gsa Capital Partners LLP | 20,472 | $65.0K | 0.01% |
| Franklin Resources Inc | 12,516 | $39.6K | 0.00% |
| Simplex Trading, LLC | 116 | $0 | 0.00% |
Sold out (4)
Institutions that held Century Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Marshall Wace, LLP | 110,316 | $382.8K |
| XTX Topco Ltd | 30,862 | $107.1K |
| Jane Street Group, LLC | 14,482 | $50.3K |
| Susquehanna International Group, LLP | 10,747 | $37.3K |